CompletedNot Applicable

Impact of High-Oleic Palm Oil Consumption on Cardiovascular Biomarkers in Adults in Bogotá

Colombia52 participantsStarted 2024-10-22

Plain-language summary

This randomized clinical trial aims to evaluate the effects of refined high-oleic palm oil consumption on cardiovascular risk biomarkers and insulin resistance in healthy adults. Participants will be randomly assigned to two groups to consume either high-oleic palm oil or olive oil for four months in typical domestic preparations.

Who can participate

Age range

18 Years – 60 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Adults aged ≥18 years * Stable medication dosages (if applicable) * Signed informed consent Exclusion Criteria: * o Use of nutritional supplements * Uncontrolled chronic diseases (e.g., diabetes, chronic kidney disease) * Allergies to palm oil or olive oil

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1This trial studied how high-oleic palm oil affects lipid profiles and blood sugar control in adults — given that I have a condition like hyperlipidemia or pre-diabetes, what do the findings from this completed study suggest about whether high-oleic palm oil is safe or beneficial for someone in my situation?
2Since this trial measured insulin resistance and glycemic biomarkers alongside cholesterol levels, does the data from this study change any recommendations my doctor might have about the types of dietary fats I should be eating?
3This trial was conducted in adults in Bogotá and is now completed — does my doctor know if the full results have been published, and whether those results would apply to my specific health profile and background?
4Because this study focused specifically on high-oleic palm oil rather than other plant-based fats, should I be asking whether standard dietary guidelines for managing Type 2 diabetes or hyperlipidemia already account for this kind of fat, or is this considered newer evidence worth factoring into my care plan?
5This trial was Phase NA, which often means it was more of an observational or nutritional study rather than a drug trial — does my doctor think the evidence from this type of study is strong enough to influence my diet, or should we wait for larger trials before making any changes?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Lipid profile

Timeframe: From the start of the intervention until the last data point is 4 months. Biochemical laboratory tests are performed every two months, meaning a total of three data points will be collected (initial, intermediate, and final).

Changes in Biomarkers of Glycemic Control and Insulin Resistance

Timeframe: Duration of the intervention: four months, with three laboratory analyses: baseline analysis at 0 month, mid-term analysis at two months, and final analysis at four months.

Trial details

NCT IDNCT07748559

SponsorRuby Alejandra Villamil

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2025-09-27

View on ClinicalTrials.gov More Insulinemic Response trials